Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CHIEF FINANCIAL OFFICER | May 11, 2023 | May 15, 2023 |
| GERON CORPGERN · Entity 4989 | EVP, CHIEF FINANCIAL OFFICER | February 17, 2026 | February 19, 2026 |
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | Chief Financial Officer | October 25, 2019 | October 30, 2019 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 11, 2023 · Filed May 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,610 |
Reported balance
After 2023-05-11 transaction · row 1
1 source rowRow 1 · 2023-05-11 · Sale · Disposed 949 · Balance 106,610 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.
GERON CORP
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,500 |
Reported balance
After 2026-02-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-18 · Exercise / conversion · Acquired 27,500 · Balance 27,500 F1: Shares of common stock acquired upon the vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 17,645 |
Reported balance
After 2026-02-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-18 · Sale · Disposed 9,855 · Balance 17,645 F2: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-16 | Direct | 1,660,000 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Grant · Acquired 1,660,000 · Balance 1,660,000 F3: The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 82,500 |
Reported balance
After 2026-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-18 · Exercise / conversion · Disposed 27,500 · Balance 82,500 F4: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F5: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock acquired upon the vesting of restricted stock units ("RSUs").
F2: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person.
F3: The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date.
F4: Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F5: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date.
MOMENTA PHARMACEUTICALS INC
Report date October 25, 2019 · Filed October 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,813 |
Reported balance
After 2019-10-25 transaction · row 1
1 source rowRow 1 · 2019-10-25 · Sale · Disposed 6,802 · Balance 6,813 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 22:19 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-066421 · tm2615478-7_4seq1.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:10 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001755098-26-000001 · form4-02192026_110201.xml · derivative · entry 4 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 27,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. F5 · derivative.expiration_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:10 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 9,855 | $1.94 | $19,118.70 |
DisclosureSEC source: 0001755098-26-000001 · form4-02192026_110201.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,645 F2 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:10 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001755098-26-000001 · form4-02192026_110201.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares of common stock acquired upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:10 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (Right to Buy) · Derivative | 1,660,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001755098-26-000001 · form4-02192026_110201.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,660,000 Underlying: Common Stock · 1,660,000 shares Expires 2036-02-16 F3 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:52 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053103 · tm2516118-9_4seq1.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:52 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053103 · tm2516118-9_4seq1.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | GERON CORP GERN · Entity 4989 | GrantRestricted Stock Units · Derivative | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024129 · ownership.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. F3 · derivative.expiration_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 656,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-024129 · ownership.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,000 Underlying: Common Stock · 656,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:31 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073608 · tm2417704-10_4seq1.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:31 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073608 · tm2417704-10_4seq1.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0000950170-24-070623 · ownership.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-09-24 F1 · derivative.exercise_date: Performance-based stock option granted on September 25, 2023 and vested in full on June 6, 2024 upon approval by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:10 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 5,291 | Not disclosed Strike: $11.44 | Not disclosed |
DisclosureSEC source: 0001104659-24-034035 · tm248737-2_4seq1.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,291 Underlying: Common Stock · 5,291 shares Expires 2034-03-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 5,291 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F1 · derivative.exercise_date: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 5,291 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:10 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 5,291 | Not disclosed Strike: $37.32 | Not disclosed |
DisclosureSEC source: 0001104659-24-034035 · tm248737-2_4seq1.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,291 shares Expires 2031-11-15 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 5,291 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F2 · derivative.exercise_date: The canceled stock option was granted on November 15, 2021 and provided for vesting in twelve equal month installments beginning on the on the last day of each month over a period from November 2021 to October 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:08 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001415889-24-004096 · form4-02162024_090217.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 14, 2024, provided the optionee continues to provide service to the Company. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 23:31 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 1,350,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001062993-23-018539 · form4.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2033-09-24 F1 · derivative.exercise_date: This option vests as follows:168,750 shares on March 25, 2024, the remaining 1,181,250 shares in a series of 42 equal monthly installments commencing March 25, 2024, provided the optionee continues to provide services to the Company. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:32 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-23-061415 · tm2315836-3_4seq1.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 949 | $9.87 | $9,368.53 |
DisclosureSEC source: 0001415889-23-007990 · form4-05152023_040503.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,610 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 184 | $8.89 | $1,635.76 |
DisclosureSEC source: 0001415889-23-004315 · form4-03062023_040309.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,559 F2 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 94,500 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001415889-23-004315 · form4-03062023_040309.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 94,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004315 · form4-03062023_040309.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,743 F1 · security: The common stock received by the Reporting person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,287 | $9.67 | $41,435.14 |
DisclosureSEC source: 0001415889-23-002603 · form4-02152023_040208.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,243 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,752 | $8.16 | $14,296.50 |
DisclosureSEC source: 0001415889-23-000875 · form4-01122023_040101.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,530 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30,2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 9,2023. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.1600 to $8.1911. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 193 | $10.23 | $1,974.39 |
DisclosureSEC source: 0001415889-22-012132 · form4-12062022_041206.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,282 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 192 | $15.01 | $2,881.92 |
DisclosureSEC source: 0001415889-22-009449 · form4-09082022_040910.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,475 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:09 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-074307 · tm2219034-8_4seq1.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 20:45 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,527 | $11.54 | $17,616.85 |
DisclosureSEC source: 0001415889-22-006161 · form4-06062022_010617.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,667 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units and in performance stock units on June 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2022 Filed Dec 20, 2022 21:08 UTC Amendment | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001104659-22-128635 · tm2232937-6_4aseq1.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-05-12 F1 · security: On June 24, 2022 the Reporting Person filed a Form 4 reporting a stock option grant which incorrectly stated an exercise price of $1.11, a transaction date of June 22, 2022 and an expiration date of June 22, 2032. This amendment is being filed to reflect the corrected exercise price of $1.07, transaction date of May 12, 2022 and expiration date of May 12, 2032. F2 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 767 | $17.33 | $13,290.35 |
DisclosureSEC source: 0001415889-22-002655 · form4-03072022_040301.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,194 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 157,580 | $0.00 Strike: $17.29 | $0.00 |
DisclosureSEC source: 0001415889-22-001223 · form4-02112022_010242.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,580 Underlying: Common Stock · 157,580 shares Expires 2032-02-09 F2 · derivative.exercise_date: This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 53,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001223 · form4-02112022_010242.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,961 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,744 | $25.70 | $44,820.80 |
DisclosureSEC source: 0001179110-22-000470 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,462 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 9, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 4,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011224 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,206 F1 · kind: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 11:10 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 63,493 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001104659-21-140263 · tm2133168-2_4seq1.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,493 Underlying: Common Stock · 63,493 shares Expires 2031-11-15 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from November, 2021 to October, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $30.65 | $0.00 |
DisclosureSEC source: 0001179110-21-008086 · edgar.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 2,500 shares Expires 2030-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. F2 · derivative.exercise_date: This option was granted on January 9, 2020 and is scheduled to vest over four years, with 25% of the shares having vested on January 9, 2021, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 9, 2024. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,500 | $60.00 | $150,000.00 |
DisclosureSEC source: 0001179110-21-008086 · edgar.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,735 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 2,500 | $30.65 | $76,625.00 |
DisclosureSEC source: 0001179110-21-008086 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $30.65 | $0.00 |
DisclosureSEC source: 0001179110-21-007175 · edgar.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,500 Underlying: Common Stock · 2,500 shares Expires 2030-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. F2 · derivative.exercise_date: This option was granted on January 9, 2020 and is scheduled to vest over four years, with 25% of the shares having vested on January 9, 2021, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 9, 2024. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,500 | $50.00 | $125,000.00 |
DisclosureSEC source: 0001179110-21-007175 · edgar.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,735 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 2,500 | $30.65 | $76,625.00 |
DisclosureSEC source: 0001179110-21-007175 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 32,197 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001179110-21-002870 · edgar.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,197 Underlying: Common Stock · 32,197 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option was granted on March 2, 2021 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2021 through March 2, 2025. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 10,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002870 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,735 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2022 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2025. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,568 | $78.27 | $122,727.36 |
DisclosureSEC source: 0001179110-21-000574 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,432 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 9, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 21:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $30.65 | $0.00 |
DisclosureSEC source: 0001179110-20-000468 · edgar.xml · derivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-01-08 F2 · derivative.exercise_date: This option was granted on January 9, 2020 and is scheduled to vest over four years, with 25% of the shares to vest on January 9, 2021 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 9, 2024. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 21:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000468 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on January 9, 2021 continuing through January 9, 2024. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:57 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 6,802 | $15.00 | $102,030.00 |
DisclosureSEC source: 0001179110-19-011271 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,813 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 20:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,936 | $13.83 | $40,604.88 |
DisclosureSEC source: 0001179110-19-011133 · edgar.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,615 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 9,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011133 · edgar.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,250 Underlying: Common Stock · 9,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 9,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-011133 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2019 Filed Apr 16, 2019 21:07 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerCommon Stock | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004996 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,801 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.